Aslan Total Current Assets vs Net Tangible Assets Analysis
ASLN Stock | USD 0.42 0.03 6.67% |
Aslan Pharmaceuticals financial indicator trend analysis is way more than just evaluating Aslan Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aslan Pharmaceuticals is a good investment. Please check the relationship between Aslan Pharmaceuticals Total Current Assets and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Total Current Assets vs Net Tangible Assets
Total Current Assets vs Net Tangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aslan Pharmaceuticals Total Current Assets account and Net Tangible Assets. At this time, the significance of the direction appears to have weak relationship.
The correlation between Aslan Pharmaceuticals' Total Current Assets and Net Tangible Assets is 0.39. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Aslan Pharmaceuticals Ltd, assuming nothing else is changed. The correlation between historical values of Aslan Pharmaceuticals' Total Current Assets and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Aslan Pharmaceuticals Ltd are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Total Current Assets i.e., Aslan Pharmaceuticals' Total Current Assets and Net Tangible Assets go up and down completely randomly.
Correlation Coefficient | 0.39 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most indicators from Aslan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aslan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. As of the 27th of April 2024, Sales General And Administrative To Revenue is likely to grow to 1.21, while Selling General Administrative is likely to drop about 9.6 M.
Aslan Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Aslan Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aslan Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.3M | 16.1M | 94.5M | 61.2M | 24.6M | 45.1M | |
Short Long Term Debt Total | 18.4M | 19.3M | 31.1M | 37.6M | 26.8M | 19.9M | |
Other Current Liab | 3.2M | 267K | 223.4K | 2.4M | 3.2M | 2.0M | |
Total Current Liabilities | 5.4M | 10.7M | 6.4M | 23.2M | 13.1M | 8.8M | |
Total Stockholder Equity | (1.7M) | (10.5M) | 57.3M | 8.4M | (13.3M) | (12.6M) | |
Other Liab | 4.8M | 8.9M | 13.4M | 112.0K | 128.8K | 122.3K | |
Net Tangible Assets | (50.3M) | (10.5M) | 57.3M | 8.4M | 7.5M | 7.1M | |
Property Plant And Equipment Net | 766.2K | 475.9K | 232.7K | 292.7K | 259.2K | 366.0K | |
Net Debt | (3.8M) | 4.9M | (59.1M) | (19.3M) | 5.6M | 5.9M | |
Retained Earnings | (179.5M) | (195.7M) | (227.0M) | (278.4M) | (321.1M) | (305.0M) | |
Accounts Payable | 1.9M | 2.3M | 3.1M | 12.8M | 7.9M | 4.4M | |
Cash | 22.2M | 14.3M | 90.2M | 56.9M | 21.3M | 40.5M | |
Non Current Assets Total | 1.1M | 579.4K | 737.4K | 307.2K | 496.5K | 471.7K | |
Non Currrent Assets Other | 108.1K | 103.3K | 10.0K | 8.6M | 1.7K | 1.6K | |
Other Assets | 7.1M | 5.3M | 103.3K | 1.0 | 1.15 | 1.09 | |
Long Term Debt | 17.6M | 15.2M | 30.9M | 29.7M | 24.8M | 23.6M | |
Cash And Short Term Investments | 22.2M | 14.3M | 90.2M | 56.9M | 21.3M | 40.5M | |
Common Stock Total Equity | 43.8M | 51.6M | 61.4M | 61.8M | 71.1M | 40.0M | |
Common Stock Shares Outstanding | 6.5M | 7.7M | 13.0M | 13.9M | 16.4M | 8.4M | |
Liabilities And Stockholders Equity | 23.3M | 16.1M | 94.5M | 61.2M | 24.6M | 45.1M | |
Non Current Liabilities Total | 18.6M | 15.6M | 30.9M | 29.7M | 24.8M | 19.4M | |
Other Current Assets | 68.9K | 649.1K | 3.6M | 4.0M | 2.7M | 2.8M | |
Other Stockholder Equity | 116.5M | 123.6M | 221.5M | 223.9M | 219.8M | 127.5M | |
Total Liab | 24.0M | 26.2M | 37.2M | 52.8M | 37.9M | 35.5M | |
Property Plant And Equipment Gross | 766.2K | 475.9K | 232.7K | 292.7K | 259.3K | 366.0K | |
Total Current Assets | 22.3M | 15.5M | 93.8M | 60.9M | 24.1M | 41.9M | |
Short Term Debt | 264.5K | 3.8M | 199.1K | 8.0M | 2.0M | 3.5M | |
Intangible Assets | 23.1M | 2.8K | 160.0 | 5.8M | 6.7M | 4.8M | |
Common Stock | 51.6M | 61.4M | 61.8M | 63.0M | 63.9M | 48.9M | |
Property Plant Equipment | 23.0M | 475.9K | 232.7K | 292.7K | 263.5K | 250.3K | |
Capital Lease Obligations | 755.4K | 552.8K | 199.1K | 215.7K | 226.2K | 238.2K | |
Non Current Liabilities Other | 161.8K | 289.6K | 447.2K | 112.0K | 128.8K | 185.3K | |
Net Invested Capital | 16.0M | 8.2M | 88.2M | 45.8M | 13.3M | 12.6M | |
Net Working Capital | 16.9M | 4.8M | 87.4M | 37.7M | 11.0M | 10.5M |
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals Ltd to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Aslan Stock analysis
When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Stocks Directory Find actively traded stocks across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Revenue Per Share 0.729 | Return On Assets (0.64) | Return On Equity (4.27) |
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.